SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Xenomics, Inc. on June 2, 2009, reporting events occurring on May 28, 2009. The filing addresses corporate governance changes rather than financial performance. Note: The request metadata references "Cardiff Oncology, Inc.," but the source document explicitly identifies the registrant as Xenomics, Inc.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 (Departure of Directors) and Item 9.01 (Exhibits) and contains no financial statements or operational data.
Material Changes
- Board Composition: On May 28, 2009, holders of a majority of outstanding shares of Common Stock delivered a consent removing Donald H. Picker, Ph.D. from his position as a director.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The primary event is the shareholder action to remove a director, documented via a Notice of Shareholder Consent dated June 2, 2009 (Exhibit 20.1).
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following the removal of Dr. Donald H. Picker.
- Confirm the reasons for the shareholder consent and any potential impact on company strategy or operations.
- Review subsequent filings for any financial updates, as this 8-K contains no financial data.